MedTrace Logo

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

NCT04249908 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-01-31

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of Besifovir and its metabolite, LB80331, in participants with normal and impaired renal function

Conditions

  • Renal Impairment

Interventions

DRUG

Besifovir Dipivoxil Maleate

Besifovir 150 mg q.d.

Sponsors & Collaborators

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-13
Primary Completion
2020-09-30
Completion
2021-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249908 on ClinicalTrials.gov